Investigational Targeted Oral Peptide JNJ-2113 Demonstrated Positive Results in Moderate-to-Severe Plaque Psoriasis in Phase 2b study Published in New England Journal of Medicine

SPRING HOUSE, Penn., Feb. 7, 2024 /PRNewswire/ -- Johnson& Johnson today announced publication in the New England Journal of Medicine (NEJM) of the Phase 2b FRONTIER 1 trial results for JNJ-2113.1 JNJ-2113 is the first and only...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials